(Q37935990)

25 August 2017

1 reference

title

Prevention of CNS relapse in diffuse large B-cell lymphoma (English)

1 reference

25 August 2017

1 reference

Robert Kridel

1

1 reference

25 August 2017

Pierre-Yves Dietrich

series ordinal

2

1 reference

25 August 2017

publication date

18 September 2011

1 reference

Lancet Oncology Commission

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

13

1 reference

25 August 2017

page(s)

1258-1266

1 reference

Therapy of diffuse large B-cell lymphomas

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lympho

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

CNS prophylaxis in lymphoma: who to target and what therapy to use.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Adult Burkitt leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Primary breast lymphoma: results of a controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Double-hit B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Involvement of chemokine receptors in breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Radioisotope CSF flow studies in leptomeningeal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Role of Intrathecal Rituximab and Trastuzumab in the Management of Leptomeningeal Carcinomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Statistical and trial design considerations in central nervous system prophylaxis studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

Response: Intrathecal methotrexate and central nervous system events

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970140-1

7 January 2021

10.1016/S1470-2045(11)70140-1

Identifiers

DOI

1 reference

25 August 2017

1 reference